Artiva Biotherapeutics Chief Tech Operations Officer Horan Christopher sold 10,366 shares at $11.16 per share on September 3, 2026. For investors, the transaction identifies both the disclosed sale price and the 283,084 shares Horan Christopher continued to own after the transaction, clarifying the reported post-sale ownership position.
Key Highlights
- Horan Christopher serves as Artiva Biotherapeutics’ Chief Tech Operations Officer.
- According to the Form 4, Horan Christopher sold 10,366 Artiva Biotherapeutics shares.
- Horan Christopher owned 283,084 Artiva Biotherapeutics shares after the transaction.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) saw Chief Tech Operations Officer Horan Christopher sell 10,366 shares at $11.16 per share. The transaction was dated September 3, 2026.
Artiva Biotherapeutics Transaction Details
The transaction carried code S and involved Artiva Biotherapeutics shares. The reported price was $11.16 per share, with 10,366 shares sold.
Post-Transaction Ownership
Horan Christopher owned 283,084 shares after the transaction. The stated holding represents the ownership position recorded following the sale.
FAQs
Q: How many Artiva Biotherapeutics shares did Horan Christopher sell?
A: According to the Form 4, Horan Christopher sold 10,366 Artiva Biotherapeutics shares. The filing reports a transaction price of $11.16 per share.
Q: What was Horan Christopher’s Artiva Biotherapeutics ownership after the sale?
A: Horan Christopher owned 283,084 Artiva Biotherapeutics shares after the transaction. The filing identifies him as the company’s Chief Tech Operations Officer.
Q: When did the Artiva Biotherapeutics share transaction occur?
A: The Artiva Biotherapeutics transaction was dated September 3, 2026. The reported sale involved Horan Christopher and carried transaction code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.